Genetics and Epigenetics of Parkinson's Disease
暂无分享,去创建一个
[1] Chuong B. Do,et al. Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database , 2012, PLoS genetics.
[2] Sonja W. Scholz,et al. Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.
[3] A. Kanthasamy,et al. Environmental Neurotoxic Pesticide Increases Histone Acetylation to Promote Apoptosis in Dopaminergic Neuronal Cells: Relevance to Epigenetic Mechanisms of Neurodegeneration , 2010, Molecular Pharmacology.
[4] N. Seki,et al. CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. , 2008, The Journal of urology.
[5] J. Stockman. Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease , 2011 .
[6] P. Lockhart,et al. DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function , 2004, Journal of Medical Genetics.
[7] J. Minna,et al. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia , 2006, International journal of cancer.
[8] A. Kanthasamy,et al. Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration. , 2011, Neurotoxicology.
[9] T. Outeiro,et al. Epigenetics in neurodegeneration: A new layer of complexity , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[10] J. Houwing-Duistermaat,et al. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. , 2001, American journal of human genetics.
[11] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[12] T. Yen,et al. The parkinsonian phenotype of spinocerebellar ataxia type 3 in a Taiwanese family. , 2004, Parkinsonism & related disorders.
[13] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[14] Yusuke Nakamura,et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.
[15] R. Obeid,et al. Biomarkers of folate and vitamin B12 status in cerebrospinal fluid , 2007, Clinical chemistry and laboratory medicine.
[16] Zhuohua Zhang,et al. Regulation of Intracellular Manganese Homeostasis by Kufor-Rakeb Syndrome-associated ATP13A2 Protein* , 2011, The Journal of Biological Chemistry.
[17] C. Woods,et al. Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36 , 2001, Journal of medical genetics.
[18] Gaofeng Wang,et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. , 2008, American journal of human genetics.
[19] M. Mancuso,et al. POLG1-Related and other “Mitochondrial Parkinsonisms”: an Overview , 2011, Journal of Molecular Neuroscience.
[20] James B. Mitchell,et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. , 2004, Cancer cell.
[21] T. Maeda,et al. Aging-associated alteration of subtelomeric methylation in Parkinson's disease. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.
[22] R. Youle,et al. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy , 2008, The Journal of cell biology.
[23] M. Ban,et al. Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson's disease , 2007 .
[24] R. Schiffmann,et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? , 2003, Molecular genetics and metabolism.
[25] Jan Gründemann,et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase , 2006, Nature Genetics.
[26] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[27] J. Kornhuber,et al. Global DNA hypomethylation and DNA hypermethylation of the alpha synuclein promoter in females with anorexia nervosa , 2007, Molecular Psychiatry.
[28] P. Lockhart,et al. Parkin genetics: one model for Parkinson's disease. , 2004, Human molecular genetics.
[29] Heidi Phillips,et al. Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.
[30] Aldo Quattrone,et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. , 2006, JAMA.
[31] F. Coppedè,et al. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. , 2009, Mutation research.
[32] S. Tsuji,et al. CpG Demethylation Enhances Alpha-Synuclein Expression and Affects the Pathogenesis of Parkinson's Disease , 2010, PloS one.
[33] D. Berg,et al. Genetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[34] R. Nussbaum,et al. Levels of alpha‐synuclein mRNA in sporadic Parkinson disease patients , 2006, Movement disorders : official journal of the Movement Disorder Society.
[35] Simon C. Potter,et al. A Two-Stage Meta-Analysis Identifies Several New Loci for Parkinson's Disease , 2011, PLoS genetics.
[36] F. Binkofski,et al. Clinical spectrum of Kufor‐Rakeb syndrome in the Chilean kindred with ATP13A2 mutations , 2010, Movement disorders : official journal of the Movement Disorder Society.
[37] P. Riederer,et al. Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability , 2008, Neurobiology of Disease.
[38] Y. Agid,et al. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. , 1998, Human molecular genetics.
[39] W. Oyen,et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome , 2009, Neurology.
[40] N. Hattori,et al. Genetic mutations and functions of PINK1. , 2011, Trends in pharmacological sciences.
[41] A. Letai,et al. Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release. , 2009, Human molecular genetics.
[42] Yan-ling Zhang,et al. HDAC6 regulates aggresome‐autophagy degradation pathway of α‐synuclein in response to MPP+‐induced stress , 2011, Journal of neurochemistry.
[43] Angela C. Poole,et al. The PINK1/Parkin pathway regulates mitochondrial morphology , 2008, Proceedings of the National Academy of Sciences.
[44] Yu Kyeong Kim,et al. Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. , 2007, Archives of neurology.
[45] Bao-Rong Zhang,et al. Study of Methylation Levels of Parkin Gene Promoter in Parkinson's Disease Patients , 2011, The International journal of neuroscience.
[46] Jun Yu,et al. Epigenetic identification of ubiquitin carboxyl‐terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors , 2008, Hepatology.
[47] Hansong Deng,et al. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila , 2008, Proceedings of the National Academy of Sciences.
[48] W. Westbroek,et al. Exploring the link between glucocerebrosidase mutations and parkinsonism. , 2011, Trends in molecular medicine.
[49] A. Contestabile,et al. Valproic Acid is Neuroprotective in the Rotenone Rat Model of Parkinson’s Disease: Involvement of α-Synuclein , 2010, Neurotoxicity Research.
[50] A. Singleton,et al. Early‐onset L‐dopa‐responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations , 2010, Movement disorders : official journal of the Movement Disorder Society.
[51] A. Kanthasamy,et al. α-Synuclein Negatively Regulates Protein Kinase Cδ Expression to Suppress Apoptosis in Dopaminergic Neurons by Reducing p300 Histone Acetyltransferase Activity , 2011, The Journal of Neuroscience.
[52] Oliver Kaut,et al. Methylation Regulates Alpha-Synuclein Expression and Is Decreased in Parkinson's Disease Patients' Brains , 2010, The Journal of Neuroscience.
[53] R. Margis,et al. Identification of blood microRNAs associated to Parkinsonĭs disease. , 2011, Journal of biotechnology.
[54] J. Hardy,et al. Genetic Analysis of Pathways to Parkinson Disease , 2010, Neuron.
[55] Eden R Martin,et al. Genome‐Wide Association Study Confirms SNPs in SNCA and the MAPT Region as Common Risk Factors for Parkinson Disease , 2010, Annals of human genetics.
[56] M. Farrer,et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. , 2007, Parkinsonism & related disorders.
[57] Mohamad Saad,et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.
[58] F. Coppedè. One-Carbon Metabolism and Alzheimer’s Disease: Focus on Epigenetics , 2010, Current genomics.
[59] V. Álvarez,et al. FGF20 rs12720208 SNP and microRNA-433 variation: No association with Parkinson's disease in Spanish patients , 2010, Neuroscience Letters.
[60] M. Goedert,et al. Tau mutations in familial frontotemporal dementia. , 2000, Brain : a journal of neurology.
[61] G. Hannon,et al. A MicroRNA Feedback Circuit in Midbrain Dopamine Neurons , 2007, Science.
[62] D. Elstein,et al. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. , 2006, Blood cells, molecules & diseases.
[63] J. Schneider,et al. Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease , 2011, Neuroscience.
[64] K. Doheny,et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease , 2009, Human Genetics.
[65] A. Verkerk,et al. Allelic imbalance of expression and epigenetic regulation within the alpha‐synuclein wild‐type and p.Ala53Thr alleles in Parkinson disease , 2010, Human mutation.
[66] R. Lu,et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin‐induced damage , 2012, British journal of pharmacology.
[67] E. Masliah,et al. Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. , 2011, The Journal of biological chemistry.
[68] O. Combarros,et al. Replication of MAPT and SNCA, but not PARK16‐18, as susceptibility genes for Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[69] R. Hawkins,et al. α‐Synuclein produces a long‐lasting increase in neurotransmitter release , 2004, The EMBO journal.
[70] J. Schulz,et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. , 2005, Human molecular genetics.
[71] M. Ronaghi,et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. , 2008, American journal of human genetics.
[72] H. Steinbusch,et al. Epigenetic regulation in the pathophysiology of Alzheimer's disease , 2010, Progress in Neurobiology.
[73] David W. Miller,et al. DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. , 2011, Human molecular genetics.
[74] R. Nass,et al. Identification of gene expression changes in transgenic C. elegans overexpressing human α-synuclein , 2006, Neurobiology of Disease.
[75] Ruben Abagyan,et al. Sirtuin 2 Inhibitors Rescue α-Synuclein-Mediated Toxicity in Models of Parkinson's Disease , 2007, Science.
[76] Xavier Estivill,et al. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. , 2011, Human molecular genetics.
[77] J. Im,et al. Repression of α-synuclein expression and toxicity by microRNA-7 , 2009, Proceedings of the National Academy of Sciences.
[78] K. Wada,et al. GIGYF2 is present in endosomal compartments in the mammalian brains and enhances IGF‐1‐induced ERK1/2 activation , 2010, Journal of neurochemistry.
[79] D. Berg,et al. Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. , 2009, Human molecular genetics.
[80] Wei Jiang,et al. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. , 2009, The Journal of clinical investigation.
[81] R. Nussbaum,et al. Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.
[82] Jan Gründemann,et al. Elevated α-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease , 2008, Nucleic acids research.
[83] R. Krüger,et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.
[84] C. Lautier,et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. , 2008, American journal of human genetics.
[85] V. Uversky,et al. Nuclear Localization of α-Synuclein and Its Interaction with Histones† , 2003 .
[86] S. Berger. The complex language of chromatin regulation during transcription , 2007, Nature.
[87] A. Kakita,et al. Accumulation of histone deacetylase 6, an aggresome‐related protein, is specific to Lewy bodies and glial cytoplasmic inclusions , 2011, Neuropathology : official journal of the Japanese Society of Neuropathology.
[88] J. Olzmann,et al. Aggresome formation and neurodegenerative diseases: therapeutic implications. , 2008, Current medicinal chemistry.
[89] J. Nutt,et al. Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease , 2007, Annals of neurology.
[90] Olaf Riess,et al. AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.
[91] R. Jiao,et al. Drosophila Histone Deacetylase 6 Protects Dopaminergic Neurons against α-Synuclein Toxicity by Promoting Inclusion Formation , 2010, Molecular biology of the cell.
[92] J. Parvin,et al. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. , 2006, Human molecular genetics.
[93] U. Rüb,et al. Spinocerebellar ataxia 2 (SCA2) , 2008, The Cerebellum.
[94] Georg Auburger,et al. The ubiquitin pathway in Parkinson's disease , 1998, Nature.
[95] Lubo Zhang,et al. Epigenetic mechanisms in developmental programming of adult disease. , 2011, Drug discovery today.
[96] E. Sidransky,et al. The Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders , 2010, Current neurology and neuroscience reports.
[97] Epaminondas Doxakis,et al. Post-transcriptional Regulation of α-Synuclein Expression by mir-7 and mir-153 , 2010, The Journal of Biological Chemistry.
[98] M. Beal,et al. Molecular insights into Parkinson's disease , 2011, F1000 medicine reports.
[99] Johannes Kornhuber,et al. DNA hypermethylation of the alpha synuclein promoter in patients with alcoholism , 2005, Neuroreport.
[100] R. Nass,et al. Global microRNA Expression Profiling of Caenorhabditis elegans Parkinson's Disease Models , 2010, Journal of Molecular Neuroscience.
[101] Carlos A. Matos,et al. Polyglutamine diseases: The special case of ataxin-3 and Machado–Joseph disease , 2011, Progress in Neurobiology.
[102] Marc Cruts,et al. Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: A Mutation Update , 2010, Human mutation.
[103] Philippe Amouyel,et al. α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.
[104] J. Hoenicka,et al. The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.
[105] Andrew Lees,et al. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.
[106] N. Sokol,et al. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression , 2010, Nature.
[107] A. Bentivoglio,et al. Novel mutations in SPG11 cause hereditary spastic paraplegia associated with early‐onset levodopa‐responsive Parkinsonism , 2011, Movement disorders : official journal of the Movement Disorder Society.
[108] M. Barrachina,et al. DNA Methylation of Alzheimer Disease and Tauopathy-Related Genes in Postmortem Brain , 2009, Journal of neuropathology and experimental neurology.
[109] U. Dillmann,et al. Methylation status and neurodegenerative markers in Parkinson disease. , 2009, Clinical chemistry.
[110] F. Gillardon,et al. MicroRNA and proteome expression profiling in early‐symptomatic α‐synuclein(A30P)‐transgenic mice , 2008, Proteomics. Clinical applications.
[111] J. Schneider,et al. Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition , 2010, Brain Research.
[112] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[113] P. Lansbury,et al. The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.
[114] M. Mehler,et al. Advances in Epigenetics and Epigenomics for Neurodegenerative Diseases , 2011, Current neurology and neuroscience reports.